Innate Pharma Files 6-K Report

Ticker: IPHYF · Form: 6-K · Filed: Jul 29, 2025 · CIK: 1598599

Innate Pharma SA 6-K Filing Summary
FieldDetail
CompanyInnate Pharma SA (IPHYF)
Form Type6-K
Filed DateJul 29, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer

TL;DR

Innate Pharma (IPHA) filed a 6-K on 7/29, check the press release for news.

AI Summary

Innate Pharma SA filed a Form 6-K on July 29, 2025, reporting a press release dated July 29, 2025. The filing is a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F. The principal executive office is located in Marseille, France.

Why It Matters

This filing provides an update on Innate Pharma's regulatory reporting status as a foreign private issuer. Investors can refer to the press release for specific business developments.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information beyond what is in the referenced press release.

Key Numbers

  • 6-K — Form Type (Standard report for foreign private issuers)

Key Players & Entities

  • Innate Pharma SA (company) — Registrant
  • July 29, 2025 (date) — Filing date and press release date
  • 001-39084 (other) — Commission File Number
  • Marseille, France (location) — Principal executive office location

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers that provides information which the issuer makes or is required to make public pursuant to the laws of its home country, or which it furnishes or makes public to its security holders.

What is the Commission File Number for Innate Pharma SA?

The Commission File Number for Innate Pharma SA is 001-39084.

Where is Innate Pharma SA's principal executive office located?

Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.

Does Innate Pharma SA file annual reports under Form 20-F or 40-F?

Innate Pharma SA indicates that it files annual reports under cover of Form 20-F.

What is the date of the press release mentioned in the filing?

The press release mentioned in the filing is dated July 29, 2025.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 29, 2025 regarding Innate Pharma SA (IPHYF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.